In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
The evolving vaccine landscape: Insights from the 6th ESCMID Conference on Vaccines
The conference brought together the vaccine community and stakeholders, including industry representatives, clinicians, regulators, policymakers, academics,...